Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00198419 · ClinicalTrials.gov registry record · Phase 1
Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase)
A Phase 1 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
NCT00198419 is a Phase 1 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 65 participants.
The verdict
NCT00198419, a Phase 1 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
Study Summary
The objective of this study was to rule out a greater than 10% incidence of hypersensitivity to Vitrase following a single intradermal injection of 3 USP units Vitrase. Less than or equal to 10% hypersensitivity response was considered acceptable.
Interventions
- DRUG Vitrase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2004-03 |
| Est. Completion | 2004-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00198419
The ClinicalTrials.gov registry entry for NCT00198419 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vitrase is the first listed.
NCT00198419 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00198419 about?
NCT00198419 is a clinical study titled "Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase)". The objective of this study was to rule out a greater than 10% incidence of hypersensitivity to Vitrase following a single intradermal injection of 3 USP units Vitrase. Less than or equal to 10% hypersensitivity response was considered acceptable.
What is the current status of trial NCT00198419?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2004-03. Estimated completion is 2004-03.
What interventions are being tested in trial NCT00198419?
The interventions under investigation include: Vitrase (DRUG).
Who is sponsoring clinical trial NCT00198419?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.